Enasidenib price in the United States

Acute myeloid leukemia (AML) is a hematologic malignancy that primarily affects older patients, with the median age at diagnosis being approximately 67 years. The overall prognosis is poor; however, new targeted therapies have emerged in recent years that may improve outcomes in these patients. Isocitrate dehydrogenase (IDH) mutations occur in 20% of AML diagnoses. IDH2 plays a vital role in cellular metabolism, and when this enzyme is inhibited, cells are unable to clear endogenous products and are therefore marked for apoptosis.

The U.S. Food and Drug Administration (FDA) approved the first mutant IDH2 inhibitor, ensidipine (Enasidenib), for patients with relapsed or refractory IDH2-mutated AML detected in an FDA-approved test. The starting dose of ensidipine is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity occurs. For patients without disease progression or unacceptable toxicity, treatment is recommended for at least 6 months to allow time for clinical response. Blood counts and blood chemistry should be evaluated before starting treatment and every 2 weeks for 3 months before treatment.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.